Hormonal
In obese non-diabetic adults, experiencing transient nausea or vomiting during dose escalation of liraglutide 3.0 mg is associated with significantly greater weight loss compared to those who do not experience these symptoms.
If you are taking liraglutide for weight loss, experiencing nausea or vomiting, especially in the first few weeks, is common and often a sign that the medication is effectively engaging your GLP-1 receptors. This side effect is linked to greater weight loss. It is usually transient and mild. Do not stop the medication abruptly; instead, discuss slower dose escalation with your provider to manage symptoms while maintaining the therapeutic benefit.
The mean 1-year weight loss on treatment with liraglutide 3.0 mg from randomization was 9.2 kg for participants reporting nausea/vomiting episodes, versus 6.3 kg for those with none (a treatment difference of 2.9 kg (95% confidence interval 0.5–5.3); P = 0.02).
Why this rating
Randomized, placebo-controlled trial with a large sample size (n=564) and long duration (2 years), though nausea data was collected via adverse event reporting rather than a specific scale.
Source
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
on behalf of the NN8022-1807 Investigators et al. · International Journal of Obesity · 2013
DOI 10.1038/ijo.2013.149
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →